Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 298-304

  Blasi, Francesco ^a,b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b San Raffaele Scientific Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

CELL ADHESION; CELL INVASION; CELL MIGRATION; CHEMOTAXIS; CONFERENCE PAPER; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

EID: 0032748523     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615846     Document Type: Conference Paper

References (78)

1. Danø K, Andreasen PA, Grøndal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985;44:139-266.
2. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: a new target for anti-metastatic therapy? T Pharmacol Sci. 1994;15:25-29.
3. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996;2:1174-1178.
4. Blasi F. u-PA, u-PAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today. 1997;18:415-419.
5. Andreasen PA, Kjøller L, Christensen L Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
6. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996;2:287-292.
7. Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in the mice. Haemostasis. 1996;Suppl 4:132-153.
8. Waltz DA, Chapman HA Jr. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994;269:14746-14750.
9. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA Jr. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380-32388.
10. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA Jr. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
11. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15:1572-1582.
12. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990;88:1-19.
13. Cubellis MV, Wun T-C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990;9:1079-1085.
14. Jensen PH, Christensen EI, Ebbesen P, Gliemann J, Andreasen PA. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul. 1990;1:1043-1056.
15. 2 macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992;267:14543-14546.
16. 2etersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Blasi F. Alpha-2 macroglobulin receptor-dependent internalization of the urokinase receptor. J Cell Biol. 1995;131:1609-1622.
17. Nykjær A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor during internalization of the u-PA-serpin complexes. EMBO J. 1997;16:2610-2620.
18. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest. 1996;97:1818-1826.
19. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in utokinase-type plasminogen activator (u-PA)-deficient and wild type mice: cellular blue nevi invade but do not progress to malignant melanoma in u-PA-deficient animals. Cancer Res. 1996;56:3597-3604.
20. Pedersen TL, Yong K, Pedersen JO, Hansen NE, Danø K, Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol. 1996;95:45-51.
21. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta-2 integrins in vivo. J Exp Med._1998;188:1029-1037.
22. Bayou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenik NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-928.
23. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 1994;8(Suppl 1):189-203.
24. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. Inhibition of tumor-cell-mediated destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci USA. 1986;83:996-1000.
25. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991;51:274-281.
26. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase. J Cell Biol. 1988;107:2437-2445.
27. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA. 1993;90:5021-5025.
28. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992;11:4825-4833.
29. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of pericytes and smooth muscle cells: a self-regulating system. J Cell Biol. 1990;111:757-763.
30. Gudewicz PW, Bilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun. 1987;147:1176-1181.
31. Boyle MD, Chiodo VA, Lawman MJ, Gee AP, Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol. 1987;139:169-174.
32. Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res. 1988;179:385-395.
33. Odekon LE, Sato Y, Rifkin D. Urokinase-type plasmionogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 1992;150:258-263.
34. Pepper MS, Sappino AP, Stöcklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993;122:673-684.
35. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994;126:259-270.
36. Gyetko MR, Todd RF III, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994;93:1380-1387.
37. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111:783-792.
38. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis. 1988;2:73-84.
39. Blasi F, Conese M, Møller LB, Pedersen N, Cavallaro U, Cubellis MV, Fazioli F, Hernandez Marrero L, Limongi P, Muñoz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis. 1994;8(Suppl 1):182-187.
40. Ellis V, Plough M. Structure-function relationship in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom a-neurotoxins. FEBS Lett. 1994;349:163-168.
41. Besser D, Verde P, Nagamine Y, Blasi F. Signal transduction and the u-PA/u-PAR system. Fibrinolysis. 1996;10:215-237.
42. Pöllänen J, Saksela O, Salonen EM, Andreasen P, Nielsen L, Danø K, Vaheri A. Distinct localization of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987;104:1085-1096.
43. Pöllänen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW. Prourokinase activation on the surface of human rhabdomyosarcoma cells: Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1990;87:2230-2234.
44. Hébert CA, Baker JB. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol. 1988;106:1241-1247.
45. Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993;41:1291-1301.
46. Degryse B, Resnati M, Rabbani A, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. In press.
47. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279-7389.
48. Picone R, Kajtaniak E, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Danø K, Blasi F. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol. 1989;108:693-702.
49. Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender JR, Blasi F, Pardi R. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest. 1996;98:1133-1141.
50. Nusrat AR, Chapman HA Jr. An autocrine role for urokinase in phorbol-ester mediated differentiation of myeloid cell lines. J Clin Invest. 1991;87:1091-1097.
51. Waltz DA, Sailor LZ, Chapman HA Jr. Cytokines induce urokinase-dependent adhesion of human myeloid cell: a regulatory role for plasminogen activator inhibitors. J Clin Invest. 1993;91:1541-1552.
52. Rao NK, Shi G-P, Chapman HA Jr. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest. 1995;96:465-474.
53. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs the urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996;134:1563-1571.
54. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996;224:344-353.
55. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Rønne E, Kobzik L, Chapman HA Jr. (1996). Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood. 1996;88:3185-3184.
56. Simon DI, Ezratty AM, Francis SA, Rennke H, LoScalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood. 1993;82:2414-2422.
57. Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta-2 integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995;181:1381-1390.
58. Xue W, Kindzelskii AL, Todd RF III, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol. 1994;152:4630-4640.
59. Kindzelskii AL, Laska ZO, Todd RF III, Petty HR. Urokinase-type plasminogen activator reversibly dissociates from complemenbt receptor type 3 (?Mb2,CD11b/CD18) during neutrophil polarization. J Immunol. 1996;157:297-3099.
60. Springer TA, Anderson DC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis and migration into inflammatory sites: insights from an experiment in nature. In: Evered D, Nugent J, O'Connor M, eds. Biochemistry of Macrophages (Ciba Foundation Symposium 118). Pittman, London; 1986:102-126.
61. vβ5-directed cell migration. J Biol Chem. 1996;271:29393-29399.
62. Cubellis MV, Andreasen PA, Ragno P, Mayer M, Danø K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1989;86:4828-4832.
63. Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989;108:1987-1995.
64. 3 binding to vitronectin. Nature. 1996;383:441-443.
65. Kjøller L, Kanse SM, Kirkegaard T, Rodenburg E, Rønne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997;232:420-429.
66. Reilly JJ Jr, Chapman HA Jr. Association between macrophage plasminogen activator activity and lung function in young cigarette smokers. Am Rev Resp Dis. 1988;138:1422-1428.
67. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA Jr. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med. 1995;322:890-895.
68. Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase to peripheral blood cells. Thromb Haemost. 1987;58:936-942.
69. Gyetko MR, Libre EA, Fuller JA, Chen G-H, Toews GB. Urokinase is required for T lymphocytes proliferation and activation in vitro. J Lab Clin Med. 1999;133:274-288.
70. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428-2435.
71. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983;35:611-619.
72. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 1988;48:1270-1277.
73. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase plasminogen activator receptyor in human squamous cell carcinoma on malignancy. EMBO J. 1994;13:3983-3991.
74. Conforti G, Dominguez-Jimenez C, Ronne E, Hoyer-Hansen G, Dejana E. Cell surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cells monolayer. Blood. 1994;83:994-1105.
75. Sølberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer. 1994;58:877-881.
76. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem. 1997;243:21-26.
77. Lund RL, Rømer J, Rønne E, Ellis V, Blasi F, Danø K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor b1 in human A549 lung carcinoma cells. EMBO J. 1991; 10:3399-3407.
78. Danø K, Rømer J, Nielson BS, Bjørn S, Pyke C, Rygaari J, Lund LR. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. Acta Pathol Microb Scand 1999; 107: 120-127.